Daptomycin for the treatment of surgical site infections

Chamberlain, Ronald S.; Culshaw, Darren; Donovan, Brian; Lamp, Kenneth C.

doi:10.1016/j.surg.2009.03.037

Cited by 25 publications

(14 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…S. aureus is an evolving management challenge for two main reasons: (i) the increasing prevalence of MRSA as the principal pathogen in surgical site infections [7]; and (ii) the growing importance of communityassociated MRSA and its contribution to healthcare-acquired infection, including necrotising fasciitis and myositis [8]. There is an increasing amount of in vitro as well as clinical evidence to support the antimicrobial treatment of such infections with daptomycin [9][10][11][12]. Based on current information, licensed dosing regimens of 4 mg/kg are appropriate for most cSSSIs.…”

Section: Discussionmentioning

confidence: 99%

Antimicrobial susceptibility of Gram-positive cocci isolated from skin and skin-structure infections in European medical centres

Sader

Farrell

Jones

2010

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Antimicrobial susceptibility of Gram-positive cocci isolated from skin and skin-structure infections in European medical centres

Sader

Farrell

Jones

2010

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

“…VRE was found to be an independent risk factor for treatment failure (odds ratio 14.2; 95% confidence interval 1.3–154). 81 …”

Section: Clinical Experience With Daptomycin In Enterococcal Infectionsmentioning

confidence: 99%

A potential role for daptomycin in enterococcal infections: what is the evidence?

Cantón

Ruíz-Garbajosa

Chaves

et al. 2010

Journal of Antimicrobial Chemotherapy

View full text Add to dashboard Cite

Nosocomial infections caused by enterococci present a challenge for clinicians because treatment options are often limited due to the widespread occurrence of strains resistant to multiple antibiotics, including vancomycin. Daptomycin is a first-in-class cyclic lipopeptide that has proven efficacy for the treatment of Gram-positive infections. Although methicillin-resistant Staphylococcus aureus has been the most prominent target in the clinical development of daptomycin, this agent has demonstrated potent bactericidal activity in enterococcal infection models and has been used for the treatment of enterococcal infections in humans. In recent years, large-scale susceptibility studies have shown that daptomycin is active against >98% of enterococci tested, irrespective of their susceptibility to other antibacterial agents. This lack of cross-resistance reflects the fact that daptomycin has a mode of action distinct from those of other antibiotics, including glycopeptides. While there are limited data available from randomized controlled trials, extensive clinical experience with daptomycin in enterococcal infections (including bacteraemia, endocarditis, skin and soft tissue infections, bone and joint infections and urinary tract infections) has been reported. This growing body of evidence provides useful insights regarding the efficacy of daptomycin against enterococci in clinical settings.

show abstract

“…The reduced susceptibility of S. aureus to Vancomycin may be partially due to biofilms, facilitating bacterial persistence [6-8]. Daptomycin, presently considered as a reliable alternative to the class of glycopeptides in these conditions [9], was recently used successfully, alone or in combination, for osteomyelitis caused by gram-positive pathogens including MRSA, unresponsive to other antibiotics [10]. Dosing of Daptomycin, however, and its ability to penetrate into inflamed target tissues are still a matter of controversy [11].…”

Section: Introductionmentioning

confidence: 99%

Successful salvage therapy with Daptomycin for osteomyelitis caused by methicillin-resistant Staphylococcus aureus in a renal transplant recipient with Fabry-Anderson disease

Polilli

Ursini

Mazzotta

et al. 2012

Ann Clin Microbiol Antimicrob

View full text Add to dashboard Cite

Daptomycin is licensed in adults for the management of Staphylococcus aureus methicillin-resistant infections, including bone and skin complicated infections. We describe for the first time its use in a renal transplant recipient for Fabry-Anderson Disease with right heel osteomyelitis. The patient was unresponsive to first-line Teicoplanin and second-line Tigecycline, whereas he was successfully treated with third-line Daptomycin monotherapy at 4 mg/Kg/qd for 4 weeks. Local debridement was performed in advance of each line of treatment.

show abstract

Daptomycin for the treatment of surgical site infections

Cited by 25 publications

References 26 publications

Antimicrobial susceptibility of Gram-positive cocci isolated from skin and skin-structure infections in European medical centres

Antimicrobial susceptibility of Gram-positive cocci isolated from skin and skin-structure infections in European medical centres

A potential role for daptomycin in enterococcal infections: what is the evidence?

Successful salvage therapy with Daptomycin for osteomyelitis caused by methicillin-resistant Staphylococcus aureus in a renal transplant recipient with Fabry-Anderson disease

Contact Info

Product

Resources

About